CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd. is a biotechnology company based in Israel that specializes in developing regenerative medicine solutions using plant-derived recombinant human collagen (rhCollagen). The company was founded in 2004 and has its headquarters in Rehovot, Israel. As of May 2021, the company had a market cap of about $94.6 million.

The vision of CollPlant is to create a new standard of care for tissue repair and organ manufacturing using its proprietary rhCollagen technology. The company has developed several products and platforms based on its rhCollagen, such as BioInks for 3D bioprinting of tissues and organs, dermal fillers for aesthetic medicine, and wound healing products for chronic and acute wounds.

One of the most notable projects of CollPlant is its collaboration with United Therapeutics Corporation to develop 3D bioprinted lungs for transplantation. In 2018, the companies signed a licensing and development agreement that granted United Therapeutics exclusive rights to use CollPlant's BioInks for lung manufacturing. In 2020, the companies announced the expansion of their partnership to include up to three additional organs.

In recognition of its innovation and leadership in the field of regenerative medicine, CollPlant received the Frost & Sullivan 2020 Technology Innovation Leadership Award for its BioInks. The award highlights the company's ability to address the unmet needs of the tissue engineering and organ manufacturing markets with its novel and versatile rhCollagen technology.

Foundation: 2004

Headquarters: Rehovot, Israel

Website: https://www.collplant.com/